The drug Tuyora contains the active ingredient tocilizumab, which blocks interleukin-6 and thereby reduces inflammation in diseases such as rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis, cytokine release syndrome and COVID-19.[1] It is indicated in adults with severe progressive rheumatoid arthritis who have not been treated with methotrexate and in adults with moderately to severely active rheumatoid arthritis.[1] Tuyory is a biosimilar medicine to the reference medicine RoActemra with the same safety and efficacy.[1] The most common side effects in patients with COVID-19 (up to 1 in 10 people) include abnormal liver function tests, constipation, and urinary tract infections.[1] The drug must not be administered in active severe infection.[1] The European Medicines Agency (EMA) issued an opinion that the benefits of Tuyora outweigh the risks and recommended its authorization in the EU.[1] The authorization date is September 15, 2023.[6] The status of the EPAR is "Opinion".[1][6]